ライフサイエンスコーパス: multikinase inhibitor

1 ive iodine who had never been treated with a multikinase inhibitor.

2 ors were also resistant to a VEGFR targeting multikinase inhibitor.

3 drives resistance of glioma cells to various multikinase inhibitors.

4 ctivity associated with several FDA-approved multikinase inhibitors.

5 peutic strategy of improving the efficacy of multikinase inhibitors.

6 Sorafenib, a multikinase inhibitor approved for the treatment of adva

7 Sorafenib, a multikinase inhibitor approved for the treatment of RCC,

8 otocols to monitor responses to sorafenib, a multikinase inhibitor approved for treatment of renal ce

9 The discovery of sorafenib, a multikinase inhibitor, as a treatment with survival bene

10 or had been treated previously with a VEGFR multikinase inhibitor (cohort 2).

11 These mutations were sensitive to the multikinase inhibitor dasatinib, which antagonizes TNK2

12 hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and ot

13 oparticle containing cabozantinib (XL184)--a multikinase inhibitor--encapsulated inside.

14 Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in

15 Indeed, sorafenib (a multikinase inhibitor) is currently being used in the su

16 previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3

17 xis in normoxia and hypoxia and suggest that multikinase inhibitors may exert antiangiogenic effects

18 Our aim was to ascertain if sorafenib, a multikinase inhibitor, may also inhibit JAK/STAT signali

19 The multikinase inhibitor META060 has been shown to inhibit

20 The multikinase inhibitor midostaurin inhibits KIT D816V, a

21 The use of multikinase inhibitors (MKI) in oncology, such as sorafe

22 GSK1363089 (foretinib), a multikinase inhibitor of AXL, MET, and vascular endothel

23 Sorafenib, a multikinase inhibitor of cell proliferation and angiogen

24 The Kit-targeting multikinase inhibitors PKC412 and dasatinib were also fo

25 tudy assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal

26 ational phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients.

27 down of MARCKS in RCC cells, the IC50 of the multikinase inhibitor regorafenib was reduced.

28 ition is a novel mechanistic explanation for multikinase inhibitor resistance in glioma cells.

29 The effects of the multikinase inhibitor sorafenib (BAY 43-9006), an agent

30 The multikinase inhibitor sorafenib (Nexavar, Bayer), used i

31 ve drug against primary hepatocarcinoma, the multikinase inhibitor Sorafenib (SFB) usually fails to e

32 We examined the interaction between the multikinase inhibitor sorafenib and histone deacetylase

33 We examined whether the multikinase inhibitor sorafenib and histone deacetylase

34 Interactions between the multikinase inhibitor sorafenib and the BH3-mimetic obat

35 Interactions between the multikinase inhibitor sorafenib and tumor necrosis facto

36 te stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in pat

37 We previously demonstrated that the multikinase inhibitor sorafenib induces apoptosis in mel

38 Only the multikinase inhibitor sorafenib is available for the man

39 advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic tre

40 In addition, the multikinase inhibitor sorafenib significantly reduces FB

41 The multikinase inhibitor sorafenib yielded similar effects

42 r rapamycin alone or in combination with the multikinase inhibitor sorafenib, all xenografts responde

43 antly, we found that the clinically valuable multikinase inhibitor sorafenib, and a natural alkaloid,

44 the kinase most efficiently inhibited by the multikinase inhibitor sorafenib, which has shown activit

45 patient before and during treatment with the multikinase inhibitor sorafenib.

46 zed with diverse drug classes, including the multikinase inhibitor sorafenib.

47 on increased the therapeutic efficacy of the multikinase inhibitor sorafenib.

48 ies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated

49 Recently a multikinase inhibitor, sorafenib, has shown survival ben

50 rapy against mCRPC-infiltrating MDSCs, using multikinase inhibitors such as cabozantinib and BEZ235,

51 h sunitinib (Sutent), an additional approved multikinase inhibitor, suggesting that the primary targe

52 The multikinase inhibitors sunitinib, sorafenib, and axitini

53 Cabozantinib is an oral multikinase inhibitor targeting MET in addition to VEGFR

54 he safety and efficacy of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, an

55 Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and

56 Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed an

57 effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculatur

58 Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had

59 Several new targeted therapies with multikinase inhibitors targeting vascular endothelial gr

60 Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial gr

61 n U.S. Food and Drug Administration-approved multikinase inhibitor that also targets Src family, dram

62 Sorafenib is a multikinase inhibitor that induces apoptosis in human le

63 Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in treating

64 sistance could be overcome with ponatinib, a multikinase inhibitor that targets BCR-ABL and FGF recep

65 This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and recept

66 BAY 43-9006, a multikinase inhibitor that targets Raf, prevents tumor c

67 Sorafenib is an oral multikinase inhibitor that targets the Ras/Raf/MEK/ERK m

68 neoplastic drug sorafenib (BAY 43-9006) is a multikinase inhibitor that targets the serine-threonine

69 Sorafenib is an oral multikinase inhibitor that was originally developed as a

70 Sorafenib is an oral, multikinase inhibitor that was recently approved for use

71 ere sensitive to treatment with sorafenib, a multikinase inhibitor, that is used for HCC treatment.

72 Sorafenib (BAY 43-9006, Nexavar) is a multikinase inhibitor with activity against Raf kinase a

73 Cabozantinib is a multikinase inhibitor with activity against RET that pro

74 Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferat

75 Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activit

76 vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity ag

77 ffects of merestinib, an orally bioavailable multikinase inhibitor with suppressive effects on Mnk ac

78 Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastat

79 ION: Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastat

80 olypharmacological approaches for developing multikinase inhibitors with low toxicity profiles.

81 hase I trial combining dasatinib, an SFK and multikinase inhibitor, with erlotinib, an EGFR inhibitor

82 FR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity again